FDA approves first targeted therapy for HER2 low breast cancer


5 August 2022 - Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an intravenous infusion for the treatment of patients with unresectable or metastatic HER2 low breast cancer. 

This is the first approved therapy targeted to patients with the HER2 low breast cancer subtype, which is a newly defined subset of HER2 negative breast cancer.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US